Immuneering (NASDAQ:IMRX) Stock, Quote.Headers.trade-ideas

Immuneering

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

IMRX

Biotech

News

Health Care

Movers

General

Immuneering reported promising initial response data from its Phase 2a trial for IMM-1-104 combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing a 40% response rate and 80% disease control rate.

Why Is Nanocap Immuneering Stock Trading Higher On Friday?

October,29,,2021,,Brazil.,In,This,Photo,Illustration,The,Meta

Earnings

Eurozone

Commodities

Markets

Trading Ideas

ALXO

ATEC

BBLG

RDHL

Vintage Wine Estates, Inc. - Common Stock

Nasdaq Surges 1%; Meta Posts Upbeat Earnings

Carvana

Pre-Market Outlook

CDNA

CFLT

CVNA

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

KXIN

NCNC

NOVA

TDOC

TENB

UDMY

Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket

Immuneering Corporation - Class A Common Stock

Immuneering Corp

The Republican party is in a frenzy to control the damage caused by the latest scandal involving North Carolina gubernatorial candidate&nbsp;Mark Robinson. They fear it could ripple beyond the state and impact Donald Trump&#8217;s 2024 <a href="https://www.benzinga.com/news/24/07/39852878/trump-says-he-is-accepting-presidential-nomination-with-faith-and-devotion-there-is-no-victory-in-wi">presidential campaign</a>.&nbsp;
What Happened: After CNN&#8217;s report on Thursday regarding Robinson&#8217;s inflammatory remarks about race, gender, and sexual preferences have left the Republicans scrambling for distance, <a href="https://thehill.com/homenews/campaign/4891581-north-carolina-gubernatorial-candidate-mark-robinson/">reported</a> The Hill.
Democrats, on the other hand, are highlighting Robinson&#8217;s connections&nbsp;to other candidates, including former&nbsp;President Trump, who has previously praised&nbsp;the North Carolina lieutenant governor.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Trump: I think Mark Robinson is one of the hottest politicians in the United States. He is a friend of mine. Thank you, Mark <a href="https://t.co/mkBsqfZEVT">pic.twitter.com/mkBsqfZEVT</a>
&mdash; Kamala HQ (@KamalaHQ) <a href="https://twitter.com/KamalaHQ/status/1836873971867763117?ref_src=twsrc%5Etfw">September 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/09/40913930/kamala-harris-moves-from-13-point-deficit-to-7-point-lead-over-trump-in-survey-of-fund-managers-stra?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Kamala Harris Moves From 13-Point Deficit To 7-Point Lead Over Trump In Survey Of Fund Managers, Strategists And Economists: Here&#8217;s Why Most Favor A Divided Government</a>
&#8220;This is a unique situation where you're not just seeing somebody who's putting the down-ballot races in jeopardy, but I think it's going to have an up-ballot effect as well,&#8221; said a Republican consultant active in North Carolina, noting that it could &#8220;really hurt&#8221; Trump&#8217;s chances of winning the state.
As per the CNN report, Robinson commented on a pornography website&#8217;s message board, self-identified as a &#8220;Black Nazi,&#8221; expressed a desire for the return of slavery, and stated a preference for Adolf Hitler over former President Barack Obama.
Robinson&#8217;s candidacy was already under scrutiny before the latest revelations. Democratic candidate Josh Stein had been leading Robinson by a significant margin in many surveys.
Despite calls for Robinson to withdraw from the race, he has vowed to stay and deemed the report fake, accusing&nbsp;the Stein campaign of leaking&nbsp;the story.
The state party issued a&nbsp;statement&nbsp;backing Robinson, accusing Democrats of&nbsp;trying to &#8220;demonize&#8221; him. However,&nbsp;other Republicans have criticized the&nbsp;comments and expressed concerns about their potential impact on the GOP&#8217;s chances in the state.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">It was a tough day, but we must stay focused on the races we can win. We have to make sure President Trump wins NC and support the outstanding GOP candidates running for key NCGA and judicial races. If Harris takes NC, she takes the White House. We can't let that happen. <a href="https://twitter.com/hashtag/ncpol?src=hash&amp;ref_src=twsrc%5Etfw">#ncpol</a>
&mdash; Thom Tillis (@ThomTillis) <a href="https://twitter.com/ThomTillis/status/1836947026543517998?ref_src=twsrc%5Etfw">September 20, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Robinson&#8217;s scandal could have a significant impact on the presidential&nbsp;race and other contests in&nbsp;North Carolina.
The Trump campaign has not directly addressed the allegations against Robinson&nbsp;but highlighted the importance of&nbsp;North Carolina to Trump&#8217;s path to victory, the report noted.
The state is a <a href="https://www.benzinga.com/general/politics/24/09/40949853/harris-in-trouble-new-swing-state-poll-shows-trump-gains-ground-in-key-battleground-areas-for-20">key battleground in the upcoming</a> 2024 presidential election. Earlier this week, a new poll of swing state voters showed that the Democratic nominee has gained one point over the former President in North Carolina.
Democrats, meanwhile, are feeling increasingly optimistic&nbsp;about their chances in the&nbsp;state. They believe that&nbsp;Stein should get a boost&nbsp;from the scandal, which could also benefit other Democrats.
This optimism appears to get some backing from data scientist Thomas Miller&#8217;s prediction, that the 2024 presidential election could see a <a href="https://www.benzinga.com/news/24/09/40950674/data-scientist-who-called-2020-election-correctly-says-its-gone-from-drastic-landslide-in-trumps-dir">drastic landslide in favor</a> of Vice President Harris.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40917216/elon-musk-says-warren-buffett-is-positioning-for-kamala-harris-win-with-his-277b-cash-pile-as-pr?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Says Warren Buffett Is Positioning For Kamala Harris Win With His $277B Cash Pile As Pro-Trumper John Paulson Warns Of Equity Market Exit</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Flickr

Politics

Media

Republicans In Damage Control Mode After Mark Robinson's Remarks Spark Concern For Trump Campaign: 'Going To Have An Up-Ballot Effect,' Says GOP Consultant

SpaceX, on Friday, continued to prepare for the fifth test flight of its Starship launch vehicle despite <a href="https://www.benzinga.com/news/24/09/40956691/spacex-ceo-elon-musk-rains-criticism-at-wrong-person-in-his-ongoing-tirade-against-faa">rising tensions with the</a> Federal Aviation Administration (FAA), the federal agency responsible for greenlighting launches. 
What Happened: SpaceX said on Friday that the fifth flight&#8217;s launch vehicle has been moved to the launching pad at its Starbase spaceport.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Flight 5 Starship moved to the pad at Starbase <a href="https://t.co/ajzPFsBCcR">pic.twitter.com/ajzPFsBCcR</a>
&mdash; SpaceX (@SpaceX) <a href="https://twitter.com/SpaceX/status/1837216036686340316?ref_src=twsrc%5Etfw">September 20, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<figcaption class="wp-element-caption">SpaceX is yet to receive the green light from the FAA for its next flight. The company said earlier this month that Starship has been&nbsp;<a href="https://www.benzinga.com/news/24/08/40305893/starship-fifth-flight-delayed-spacex-ceo-elon-musk-gives-fresh-august-end-timeline" target="_blank" rel="noreferrer noopener">ready for its fifth flight test</a>&nbsp;since the first week of August but has been put off owing to &#8220;frivolous&#8221; and &#8220;patently absurd&#8221; licensing issues. &#8220;Unfortunately, we continue to be stuck in a reality where it takes longer to do the government paperwork to license a rocket launch than it does to design and build the actual hardware,&#8221; SpaceX said.</figcaption></figure>
The company said that it recently received a launch license date estimate of late November for the fifth flight from the FAA, marking a two-month delay from the previously communicated date of mid-September.
The delay, SpaceX said, was not based on a new safety concern but on &#8220;superfluous&#8221; environmental analysis including concerns about the Starbase facility having a negative impact on local flora and fauna. However, the company disputed these claims.
Why It Matters: Earlier this week, SpaceX also tested the engines of its Starship launch vehicle for its sixth flight test.
"Flight 5 is built and ready to fly. Flight 6 will be ready to fly before Flight 5 even gets approved by FAA!" SpaceX CEO&nbsp;Elon Musk&nbsp;said on Thursday.
The Starship&#8217;s last test flight was conducted in June. For the upcoming flight, SpaceX&#8217;s goal is to&nbsp;catch Starship&#8217;s&nbsp;<a href="https://www.benzinga.com/news/24/06/39543299/spacex-preparing-to-catch-starship-booster-at-starbase-during-next-test-flight-instead-of-splashing" target="_blank" rel="noreferrer noopener">booster stage back at Starbase</a>&nbsp;using the launch tower's mechanical arms, marking a significant demonstration of Starship&#8217;s reusability.
Earlier this week, the FAA also proposed a fine of $633,009 on SpaceX for allegedly failing to follow its license requirements during two launches in 2023.
SpaceX Vice President for Legal David Harris subsequently<a href="https://www.benzinga.com/markets/equities/24/09/40951122/elon-musk-blasts-faa-for-targeting-spacex-over-petty-matters-while-ignoring-boeings-safety-issue" target="_blank" rel="noreferrer noopener">&nbsp;sent a letter addressed to key members&nbsp;</a>of the U.S. Congress, including Rep.&nbsp;Frank Lucas&nbsp;(R-Okla.) and Rep.&nbsp;Zoe Lofgren&nbsp;(D-Calif.), Sen.&nbsp;Ted Cruz&nbsp;(R-Texas) and Senate Commerce Committee Chair&nbsp;Maria Cantwell&nbsp;(D-Wash.) denying the FAA's allegations of regulatory violations while also alleging that the federal agency lacks the resources to review licensing commercial spaceflight operations.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40954673/rivian-introduces-100k-tri-max-variant-of-r1s-electric-suv-on-online-shop-which-can-go-from-0-60-mph">Rivian Introduces $100K Tri Max Variant Of R1S Electric SUV On Online Shop Which Can Go from 0-60 MPH In 3s</a></li>
</ul>
Photo via Shutterstock

SPACE

Tech

SpaceX Pushes Ahead With Fifth Starship Test Flight Preparation Despite No FAA Launch Approvals In Sight

JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) CEO Jamie Dimon has called for federal employees in Washington, DC, to return to their offices, highlighting the ongoing debate over <a href="https://www.benzinga.com/top-stories/24/09/40887347/amazon-to-cut-management-layers-end-work-from-home">remote work policies.</a>
What Happened: Speaking at The Atlantic Festival, Dimon expressed his frustration with the number of empty buildings in the capital, <a href="https://www.businessinsider.com/jamie-dimon-dc-federal-workers-should-go-back-to-office-2024-9">according</a> to Business Insider on Friday.
&#8220;By the way, I&#8217;d also make Washington, DC, go back to work. I can&#8217;t believe, when I come down here, the empty buildings. The people who work for you not going to the office,&#8221; he stated,
 &#8220;That bothers me,&#8221; he added. Dimon emphasized that he does not allow such flexibility at JPMorgan.
See Also: <a href="https://www.benzinga.com/news/24/09/40931458/obama-era-economist-says-she-is-pleasantly-surprised-that-jd-vance-thinks-the-economy-is-too-strong?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Obama-Era Economist Says She Is &#8216;Pleasantly Surprised&#8217; That JD Vance Thinks The &#8216;Economy Is Too Strong For The Rate Cut&#8217;</a>
Why It Matters: Dimon is not alone in his stance. Earlier this week, Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) CEO Andy Jassy announced that Amazon employees would <a href="https://www.benzinga.com/markets/equities/24/09/40912814/amazon-told-its-staff-they-must-come-to-office-five-days-a-week-but-its-primary-healthcare-subsi">return to the office five days a wee</a>k, reverting to pre-pandemic norms.
JPMorgan&#8217;s policy mandates managing directors to be in the office full-time, while other employees must work in person at least three days a week. Last year, the Biden Administration also <a href="https://www.benzinga.com/real-estate/23/08/33670485/biden-tells-remote-federal-workers-to-come-back-as-washington-d-c-office-occupancy-rates-plummet">pushed federal employees </a>to return to in-person work.
Despite these efforts, many federal workers still have flexible work arrangements. For instance, some Environmental Protection Agency employees are required to be in the office only four days a month. Other agencies, like the Department of the Treasury and the Department of the Interior, require at least 50% in-office presence.
Office vacancy rates in DC remain high, with about 22% of <a href="https://www.benzinga.com/real-estate/reit/24/07/40037113/work-from-home-has-hit-office-real-estate-the-hardest-in-these-5-us-cities">office space empty </a>in the second quarter of 2024, according to CBRE. The federal government and private-sector offices contribute to this trend.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/news/24/09/40939390/trump-media-technology-group-stock-slides-as-lockup-expiration-looms-whats-going-on?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Media &amp; Technology Group Stock Slides As Lockup Expiration Looms: What&#8217;s Going On?</a></li>
</ul>
This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image via Flickr/ Frank Gruber

AMZN

JPMorgan CEO Jamie Dimon Calls For Federal Employees To Return To Office, Says Empty Buildings 'Bother' Him: 'I Can't Believe...'

OTRK

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

TRAW

RSLS

Owning a home can give some people confidence about their retirement prospects, but experts warn that this confidence might be misplaced.
According to the Your Money Retirement Survey conducted by SurveyMonkey and CNBC.com, about 37% of workers – including those employed part-time, full-time, self-employed, or as business owners – believe they are "ahead of schedule" (7%) or "on schedule" (30%) with their retirement savings.
Don't Miss:
<ul>
<li>The number of ‘401(k)' Millionaires is up 43% from last year —<a href="https://www.benzinga.com/money/401k-millionaires"> Here are three ways to join the club.</a></li>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
<li>Miami is expected to take New York's place as the U.S. Financial Capital.<a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital"> Here's how you can invest in the city before that happens</a>.</li>
</ul>
Among those who feel on track, 42% attribute their progress to starting<a href="https://www.benzinga.com/personal-finance/24/05/38793057/can-you-guess-how-many-retire-with-a-5-million-nest-egg"> retirement savings</a> early. Other key factors contributing to their preparedness include having little to no debt (38%) and home equity or ownership (37%).
The August survey gathered responses from 6,657 adults, including 2,603 retirees and 4,054 working adults.
See Also: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
Angie Chen, a senior research economist and assistant director of savings research at the Center for Retirement Research at Boston College, suggests that homeowners' confidence in their home's value as a source of retirement wealth may be misguided.
"Homeowners are actually more likely to be overconfident in their retirement readiness," Chen told CNBC. "There's a lot of misconception in terms of how people assess whether they are ahead or not in retirement."
Nevertheless, Winnie Sun, co-founder and managing director of Sun Group Wealth Partners in Irvine, California, points out that homeownership can offer other benefits during retirement.
Trending: This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a>
The Center for Retirement Research's (CRR) National Retirement Risk Index (NRRI) gauges the percentage of working-age households at risk of being financially unprepared for retirement. A 2023 CRR analysis revealed that 28% of people believe they are not at risk, despite the NRRI indicating otherwise.
"People who own houses but still owe a lot on their houses are much more likely to be overconfident or not worried enough," Chen said.
Trending: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.
To accurately assess retirement preparedness, Chen emphasizes the importance of considering not just the value of your home but also the amount you have borrowed and still owe.
For instance, if you purchased a $500,000 home but still owe $400,000, your actual equity is $100,000. Experts caution that accessing this equity can be costly and risky, as borrowing against your home is not always straightforward.
"<a href="https://www.benzinga.com/personal-finance/24/06/39234360/my-struggling-73-year-old-dad-owes-45-000-on-his-mortgage-and-15-000-on-a-heloc-should-he-sell-o">Housing is not liquid</a>," Chen said. "You might feel good about having this large asset, but you can't consume that in retirement. You can't spend it so that you can spend and consume other savings."
Trending: Founder of Personal Capital and ex-CEO of PayPal<a href="https://www.benzinga.com/money/evergreen-money"> re-engineers traditional banking with this new high-yield account — start saving better today.</a>
Experts also point out some advantages to homeownership.
Owning a home offers financial benefits even if you're not factoring in home equity for retirement. First, you build equity in your home. Sun said that when you sell the property, such as when downsizing in retirement, you can access that equity as a lump sum.
Additionally, while you own the property, you have a fixed housing cost, typically including a stable mortgage payment. Despite rising costs for home insurance and property taxes in recent years, you might be eligible for senior discounts on utilities by the time you retire.
Although a house is not a liquid asset, experts suggest you can still access your home equity if needed.
"In most cases for retirees, they kind of see equity as their emergency fund," Sun said.
Read Next:
<ul>
<li> Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/irs-finalizes-10-year-rule-adv">IRS Finalizes 10-Year Rule For Retirement Withdrawals, Making Things &#8216;Even More Insanely Complicated&#8217;</a></li>
</ul>

Personal Finance

Retirement Ready? Think Again As Experts Warn Homeowners Still Paying Mortgages That They 'Are Much More Likely To Be Overconfident'

Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) has outperformed the market over the past 5 years by 11.84% on an annualized basis producing an average annual return of 25.79%. Currently, Oracle has a market capitalization of $465.52 billion. 
Buying $1000 In ORCL: If an investor had bought $1000 of ORCL stock 5 years ago, it would be worth $3,109.96 today based on a price of $168.00 for ORCL at the time of writing.
<h3>Oracle's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726867809_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ORCL

Here's How Much You Would Have Made Owning Oracle Stock In The Last 5 Years

In the latest quarter, 4 analysts provided ratings for ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated ADMA Biologics and provided 12-month price targets. The average target is $18.25, accompanied by a high estimate of $20.00 and a low estimate of $15.00. Marking an increase of 32.73%, the current average surpasses the previous average price target of $13.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1726866079_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive ADMA Biologics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ADMA Biologics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of ADMA Biologics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of ADMA Biologics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into ADMA Biologics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ADMA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ADMA Biologics analyst ratings.</a>
<h2>Get to Know ADMA Biologics Better</h2>
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
<h3>Understanding the Numbers: ADMA Biologics's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: ADMA Biologics's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 78.29%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: ADMA Biologics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 29.91%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): ADMA Biologics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 18.75%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): ADMA Biologics's ROA excels beyond industry benchmarks, reaching 8.82%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.75, ADMA Biologics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ADMA

In-Depth Examination Of 4 Analyst Recommendations For ADMA Biologics

In the last three months, 10 analysts have published ratings on Renasant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNST#NYSE">RNST</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Renasant, presenting an average target of $36.9, a high estimate of $41.00, and a low estimate of $32.00. Observing a 7.83% increase, the current average has risen from the previous average price target of $34.22. 
<img src="https://www.benzinga.com/files/images/story/2024/1726866068_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Renasant among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$37.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Stephen Scouten</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Catherine Mealor</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Matt Olney</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$41.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>David Bishop</td>
<td>Hovde Group</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$38.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Catherine Mealor</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$36.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$32.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Stephen Scouten</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Catherine Mealor</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Renasant. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Renasant compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Renasant's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Renasant's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RNST/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Renasant analyst ratings.</a>
<h2>About Renasant</h2>
Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has three reportable segments: community banks, insurance, and wealth management. With its community banks segment, the company provides a range of financial services to individuals and small businesses. Its insurance segment is an insurance agency providing commercial and personal insurance through third-party carriers. The wealth management segment provides a range of services including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment. Renasant Corporation operates in the southern United States.
<h3>Financial Insights: Renasant</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Renasant's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 11.09%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Renasant's net margin excels beyond industry benchmarks, reaching 23.72%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Renasant's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.66% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Renasant's ROA excels beyond industry benchmarks, reaching 0.22%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.28, Renasant adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RNST

A Closer Look at 10 Analyst Recommendations For Renasant

Cathay General (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATY#NASDAQ">CATY</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Cathay General and provided 12-month price targets. The average target is $44.5, accompanied by a high estimate of $50.00 and a low estimate of $36.00. This upward trend is apparent, with the current average reflecting a 11.95% increase from the previous average price target of $39.75.
<img src="https://www.benzinga.com/files/images/story/2024/1726866059_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Cathay General is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$47.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$45.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Matthew Clark</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Underweight</td>
<td>$36.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Cathay General. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cathay General compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Cathay General's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Cathay General's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CATY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cathay General analyst ratings.</a>
<h2>All You Need to Know About Cathay General</h2>
Cathay General Bancorp is a regional bank predominantly serving the Chinese-American community. The company's policy is to reach out and actively offer services to low-to-moderate income groups in the delineated branch service areas. It predominantly provides services such as checking and deposit, lines of credits, commercial and commercial real estate loans, merchant services and payment processing, treasury management services, international banking and financing services, and other customary banking services to individuals, professionals, and small to medium-sized businesses. Through its Wealth Management unit, the company also offers investment products and services, such as stocks, bonds, mutual funds, insurance, annuities, and advisory services.
<h3>Cathay General's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Cathay General's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -12.76%. This indicates a decrease in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Cathay General's net margin excels beyond industry benchmarks, reaching 37.43%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Cathay General's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.4%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Cathay General's ROA stands out, surpassing industry averages. With an impressive ROA of 0.29%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Cathay General's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.12.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CATY

Unveiling 4 Analyst Insights On Cathay General

During the last three months, 4 analysts shared their evaluations of First Finl Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIN#NASDAQ">FFIN</a>), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $36.5, with a high estimate of $40.00 and a low estimate of $31.00. This upward trend is apparent, with the current average reflecting a 9.77% increase from the previous average price target of $33.25.
<img src="https://www.benzinga.com/files/images/story/2024/1726866050_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of First Finl Bankshares among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$40.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$39.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Matt Olney</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$36.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$31.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to First Finl Bankshares. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of First Finl Bankshares compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of First Finl Bankshares's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into First Finl Bankshares's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FFIN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on First Finl Bankshares analyst ratings.</a>
<h2>Discovering First Finl Bankshares: A Closer Look</h2>
First Financial Bankshares Inc is a financial and bank holding company. The company operates one line of business (community banking) located in a single geographic area (Texas). The company conducts a full-service commercial banking business through its subsidiaries. The loan portfolio segments of the company include Commercial and Industrial, Municipal, Agricultural, Construction and Development, Farm, Non-Owner Occupied and Owner Occupied Commercial Real Estate, Residential, Consumer Auto and Consumer Non-Auto.
<h3>Financial Insights: First Finl Bankshares</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, First Finl Bankshares showcased positive performance, achieving a revenue growth rate of 7.11% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: First Finl Bankshares's net margin is impressive, surpassing industry averages. With a net margin of 40.04%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.49%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.4%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FFIN

Analyst Ratings For First Finl Bankshares

6 analysts have shared their evaluations of Live Oak Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOB#NYSE">LOB</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $47.33, a high estimate of $57.00, and a low estimate of $38.00. This current average reflects an increase of 13.15% from the previous average price target of $41.83. 
<img src="https://www.benzinga.com/files/images/story/2024/1726866035_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Live Oak Bancshares among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$57.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Timothy Switzer</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$47.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$38.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Steven Alexopoulos</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$46.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Live Oak Bancshares. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Live Oak Bancshares compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Live Oak Bancshares's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LOB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Live Oak Bancshares analyst ratings.</a>
<h2>All You Need to Know About Live Oak Bancshares</h2>
Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.
<h3>Unraveling the Financial Story of Live Oak Bancshares</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Live Oak Bancshares's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 15.27% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Live Oak Bancshares's net margin excels beyond industry benchmarks, reaching 21.85%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Live Oak Bancshares's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.86% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Live Oak Bancshares's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.23% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Live Oak Bancshares's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.12.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 6 Analyst Projections For Live Oak Bancshares

Coca-Cola Consolidated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COKE#NASDAQ">COKE</a>) has outperformed the market over the past 10 years by 21.34% on an annualized basis producing an average annual return of 32.55%. Currently, Coca-Cola Consolidated has a market capitalization of $11.08 billion. 
Buying $1000 In COKE: If an investor had bought $1000 of COKE stock 10 years ago, it would be worth $16,450.88 today based on a price of $1264.25 for COKE at the time of writing.
<h3>Coca-Cola Consolidated's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726866016_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COKE

Here's How Much You Would Have Made Owning Coca-Cola Consolidated Stock In The Last 10 Years

Across the recent three months, 12 analysts have shared their insights on Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $23.67, a high estimate of $28.00, and a low estimate of $21.00. Marking an increase of 7.59%, the current average surpasses the previous average price target of $22.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1726866015_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Regions Finl's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Erika Najarian</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>David Konrad</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Kenneth Usdin</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Regions Finl. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Regions Finl compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Regions Finl's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Regions Finl's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RF/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Regions Finl analyst ratings.</a>
<h2>Unveiling the Story Behind Regions Finl</h2>
Regions Financial is a regional bank headquartered in Alabama, with branches primarily in the Southeastern and Midwestern United States. Regions primarily provides traditional commercial and retail banking and also offers mortgage services, asset management, wealth management, securities brokerage, and trust services.
<h3>Regions Finl: Financial Performance Dissected</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Challenges: Regions Finl's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -11.55%. This indicates a decrease in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 27.56%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Regions Finl's ROE stands out, surpassing industry averages. With an impressive ROE of 3.09%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Regions Finl's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.31%, the company showcases efficient use of assets and strong financial health.
Debt Management: Regions Finl's debt-to-equity ratio is below the industry average at 0.36, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

12 Analysts Have This To Say About Regions Finl

Gartner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) has outperformed the market over the past 15 years by 13.06% on an annualized basis producing an average annual return of 24.88%. Currently, Gartner has a market capitalization of $39.86 billion. 
Buying $1000 In IT: If an investor had bought $1000 of IT stock 15 years ago, it would be worth $28,516.94 today based on a price of $517.24 for IT at the time of writing.
<h3>Gartner's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726866011_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Gartner Stock In The Last 15 Years

Deep-pocketed investors have adopted a bullish approach towards Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CAT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 22 extraordinary options activities for Caterpillar. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 45% leaning bullish and 36% bearish. Among these notable options, 14 are puts, totaling $1,288,875, and 8 are calls, amounting to $389,403.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $310.0 and $450.0 for Caterpillar, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Caterpillar options trades today is 723.82 with a total volume of 11,962.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Caterpillar's big money trades within a strike price range of $310.0 to $450.0 over the last 30 days.
<h3>Caterpillar Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726865250_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$9.15</td>
<td>$9.0</td>
<td>$9.07</td>
<td>$350.00</td>
<td>$546.3K</td>
<td>1.2K</td>
<td>634</td>
</tr>
<tr>
<td>CAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.65</td>
<td>$5.3</td>
<td>$5.65</td>
<td>$450.00</td>
<td>$141.2K</td>
<td>136</td>
<td>250</td>
</tr>
<tr>
<td>CAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/01/24</td>
<td>$7.55</td>
<td>$6.85</td>
<td>$6.85</td>
<td>$350.00</td>
<td>$123.3K</td>
<td>27</td>
<td>200</td>
</tr>
<tr>
<td>CAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$9.05</td>
<td>$8.95</td>
<td>$9.02</td>
<td>$350.00</td>
<td>$95.5K</td>
<td>1.2K</td>
<td>1.3K</td>
</tr>
<tr>
<td>CAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$8.8</td>
<td>$8.75</td>
<td>$8.79</td>
<td>$350.00</td>
<td>$89.7K</td>
<td>1.2K</td>
<td>1.5K</td>
</tr>
</tbody>
</table>

<h3>About Caterpillar</h3>
Caterpillar is the top manufacturer of heavy equipment, power solutions, and locomotives. It is currently the world's largest manufacturer of heavy equipment. The company is divided into four reportable segments: construction industries, resource industries, energy and transportation, and Cat Financial. Its products are available through a dealer network that covers the globe with about 2,700 branches maintained by 160 dealers. Cat Financial provides retail financing for machinery and engines to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Caterpillar product sales.
Following our analysis of the options activities associated with Caterpillar, we pivot to a closer look at the company's own performance.
<h3>Current Position of Caterpillar</h3>
<ul>
<li>With a volume of 5,177,212, the price of CAT is down -1.13% at $369.1. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 39 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Caterpillar options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

What the Options Market Tells Us About Caterpillar

Whales with a lot of money to spend have taken a noticeably bearish stance on Visa.
Looking at options history for Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) we detected 19 trades.
If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations and 52% with bearish.
From the overall spotted trades, 15 are puts, for a total amount of $875,964 and 4, calls, for a total amount of $279,465.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $230.0 to $300.0 for Visa over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Visa stands at 446.8, with a total volume reaching 1,862.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Visa, situated within the strike price corridor from $230.0 to $300.0, throughout the last 30 days.
<h3>Visa Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726865245_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>V</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$34.55</td>
<td>$33.75</td>
<td>$34.0</td>
<td>$250.00</td>
<td>$170.0K</td>
<td style="text-align: right;">229</td>
<td style="text-align: right;">52</td>
</tr>
<tr>
<td>V</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$19.0</td>
<td>$18.75</td>
<td>$18.8</td>
<td>$300.00</td>
<td>$99.5K</td>
<td style="text-align: right;">49</td>
<td style="text-align: right;">106</td>
</tr>
<tr>
<td>V</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$14.25</td>
<td>$14.0</td>
<td>$14.14</td>
<td>$295.00</td>
<td>$77.9K</td>
<td style="text-align: right;">340</td>
<td style="text-align: right;">343</td>
</tr>
<tr>
<td>V</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$14.1</td>
<td>$13.8</td>
<td>$13.99</td>
<td>$295.00</td>
<td>$77.4K</td>
<td style="text-align: right;">340</td>
<td style="text-align: right;">288</td>
</tr>
<tr>
<td>V</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$15.5</td>
<td>$15.25</td>
<td>$15.45</td>
<td>$295.00</td>
<td>$69.5K</td>
<td style="text-align: right;">129</td>
<td style="text-align: right;">154</td>
</tr>
</tbody>
</table>

<h3>About Visa</h3>
Visa is the largest payment processor in the world. In fiscal 2023, it processed almost $15 trillion in total volume. Visa operates in over 200 countries and processes transactions in over 160 currencies. Its systems are capable of processing over 65,000 transactions per second.
Having examined the options trading patterns of Visa, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Visa</h3>
<ul>
<li>With a volume of 27,553,349, the price of V is down -0.43% at $284.0. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 32 days.</li>
</ul>
<h3>What Analysts Are Saying About Visa</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $314.6666666666667.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Compass Point lowers its rating to Buy with a new price target of $319. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Neutral rating for Visa, targeting a price of $308. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Visa with a target price of $317. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Visa with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Visa's Options Frenzy: What You Need to Know

Benzinga's options scanner just detected over 8 options trades for JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) summing a total amount of $1,462,072.
At the same time, our algo caught 4 for a total amount of 1,325,899.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $25.0 to $30.0 for JD.com during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for JD.com's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of JD.com's whale activity within a strike price range from $25.0 to $30.0 in the last 30 days. 
<h3>JD.com Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726865239_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.75</td>
<td>$3.65</td>
<td>$3.66</td>
<td>$30.00</td>
<td>$1.0M</td>
<td>230</td>
<td>3.0K</td>
</tr>
<tr>
<td>JD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.96</td>
<td>$0.94</td>
<td>$0.94</td>
<td>$25.00</td>
<td>$94.0K</td>
<td>22.3K</td>
<td>2.0K</td>
</tr>
<tr>
<td>JD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.99</td>
<td>$0.94</td>
<td>$0.94</td>
<td>$25.00</td>
<td>$94.0K</td>
<td>22.3K</td>
<td>1</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$1.05</td>
<td>$1.03</td>
<td>$1.06</td>
<td>$27.50</td>
<td>$54.6K</td>
<td>31.4K</td>
<td>875</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$1.0</td>
<td>$0.96</td>
<td>$0.99</td>
<td>$27.50</td>
<td>$52.9K</td>
<td>31.4K</td>
<td>2.6K</td>
</tr>
</tbody>
</table>

<h3>About JD.com</h3>
JD.com is a leading e-commerce platform with its 2022 China GMV being similar to Pinduoduo (GMV not reported), on our estimate, but still lower than Alibaba. it offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Having examined the options trading patterns of JD.com, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of JD.com</h3>
<ul>
<li>Trading volume stands at 9,633,570, with JD's price down by -0.56%, positioned at $28.58.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 54 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for JD.com, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

What the Options Market Tells Us About JD.com

FLUMIST Receives Approval For Self-Administration In U.S.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Various names in the biotech sector are seeing big moves in today&rsquo;s session, as investors are clearly interested in rotation into a number of higher-growth small-cap stocks. Immuneering (NASDAQ:<a href="https://investorplace.com/stock-quotes/imrx-stock-quote/">IMRX</a>) is certainly one such company generating outsized interest today. At the time of this writing, IMRX stock has surged more than 24% on news that the company was <a href="https://finance.yahoo.com/news/immuneering-granted-fda-fast-track-200500701.html">granted a fast track designation</a> for its IMM-1-104 drug by the U.S. Food and Drug Administration (FDA).



This drug is aimed at patients suffering from pancreatic cancer and the fast track designation has reportedly been granted for patients suffering from both first- and second-line pancreatic ductal adenocarcinoma. The hope is that this designation will accelerate the company&rsquo;s path to official approval of the drug, with a Phase 2a trial underway studying the impact of the treatment on pancreatic cancer, RAS-mutant melanoma and RAS-mutant lung cancer.



Let&rsquo;s dive more into <a href="https://immuneering.com">what Immuneering does</a> and why IMRX stock is surging.



<h2>IMRX Stock Soars on Fast Track Designation from the FDA</h2>



Aside from an outright FDA approval for a particular drug, a fast track designation is one of the key catalysts many biotech investors like to see. Such designations allow prospective drugs to have an accelerated timeline for approval and typically rely on positive clinical trial data and strong efficacy arguments in order to be granted.



For investors in Immuneering, a clinical-stage oncology company focused on a range of cancers, this initial fast track designation is something many investors have clearly wanted. With a market capitalization of a little more than $40 million (after today&rsquo;s rise), it&rsquo;s clear this news improves the company&rsquo;s prospective pathway to profitability moving forward. If this drug is officially approved at the end of the day for the range of cancer patients Immuneering is seeking to help, IMRX stock could have big-time upside worth considering.



Of course, there are plenty of risks to consider with such an investment as well. It&rsquo;s unclear how long such a process will take (though the timeline has been greatly improved by this designation). Cash burn concerns and time to market are the key factors at play right now. That said, while uncertainty remains, this is a stock that has also moved up on the watch lists of many biotech investors today &mdash; and rightfully so. I&rsquo;ll be watching IMRX stock closely and aim to provide additional updates as they come moving forward.



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, Chris MacDonald did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines.</a>



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Chris MacDonald&rsquo;s love for investing led him to pursue an MBA in Finance and take on a number of management roles in corporate finance and venture capital over the past 15 years. His experience as a financial analyst in the past, coupled with his fervor for finding undervalued growth opportunities, contribute to his conservative, long-term investing perspective.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/why-is-immuneering-imrx-stock-up-24-today/">Why is Immuneering (IMRX) Stock Up 24% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why is Immuneering (IMRX) Stock Up 24% Today?

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immuneering (IMRX – Research Report), Eli Lilly & Co...

Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Eli Lilly & Co (LLY) and Teva Pharmaceutical (TEVA)

Immuneering reports Q2 results

Immuneering stock rockets 45% on pancreatic therapy data

In a report released today, Ami Fadia from Needham maintained a Buy rating on Immuneering (IMRX – Research Report), with a price target of $15.00. ...

Positive Phase 2a Trial Data Reinforces Buy Rating for Immuneering's Stock

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Immuneering (IMRX – Research Report), McKesson (MC...

Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), McKesson (MCK) and Neurocrine (NBIX)

Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on IMRX stock, giving a Buy rating on September 12. Graig Suvannave...

Outperform Rating Reaffirmed for Immuneering's Stock Amidst Promising IMM-1-104 Phase 2a Study Results

Smith Micro Software, Datasea, and Immuneering Corp. are the 3 Penny Stocks to watch on September 18, 2024, based on&nbsp;TipRanks' Penny Stock Scr...

3 Penny Stocks to Watch Now, 9/18/24

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immuneering (IMRX – Research Report) and IO Biotech ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC speakers

AERG

AZUL

BIRK

BMRN

BRZE

COST

DTSS

ETON

HUBS

IART

INTU

IOBT

LUNR

MPAA

NBIX

NXST

PGHL

SFIX

SMSI

TEVA

VERV

VSTO

ZETA

Press Releases

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Immuneering Recognizes Melanoma Awareness Month

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

Small Cap

Opinion

Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment

Immuneering to Present at the Jefferies Global Healthcare Conference

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Immuneering

Immuneering (IMRX) Forecast

Immuneering (NASDAQ:IMRX) Stock, Quote.Headers.trade-ideas